Results 31 to 40 of about 39,159 (175)

Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy

, 2002
Objective: To evaluate HIV-1 reverse transcriptase (RT) drug resistance in patients receiving abacavir, lamivudine and zidovudine therapy. Methods: In a randomized, double-blind study, 173 antiretroviral treatment-naive HIV-1-infected adults received ...
Pulido Ortega, Federico, Lafon, Steve, Ait-Khaled, Mounir, Rubio García, Rafael   +3 more
core   +2 more sources

Management of Antiviral Resistance in Chronic Hepatitis B

Gut and Liver, 2017
The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment.
Young-Suk Lim
doaj   +1 more source

Treatment of subacute hepatitis B with lamivudine: A pilot study in Serbia [PDF]

Vojnosanitetski Pregled, 2009
Background/Aim. The incidence of acute hepatitis B viral (HBV) infection in adults has increased in recent years in Serbia. Most icteric patients with acute hepatitis B resolve their infection and do not require treatment.
Delić Dragan, Nešić Zorica, Prostran Milica, Boričić Ivan, Svirtlih Neda   +4 more
doaj   +1 more source

Molecular Signatures of HIV‐Induced Neuroinflammation and Neurodegeneration in Human Cerebral Organoids: Identification of Therapeutic Targets for NeuroHIV

Advanced Science, EarlyView.
HIV preferentially infects microglia, activating IL‐17A‐driven IFN‐γ/STAT1, CEBPB, and NF‐κB signaling that converges with cGAS‐STING and Notch–NEURL1 pathways, promoting neuroinflammation, mitochondrial dysfunction, and synaptic impairment. cART suppresses viral replication, attenuates inflammatory signaling, and at least partially restores ...
Karthick Chennakesavan, Malaroviyam Samikkannu, Shreyan Gupta, Olasunkanmi Israel Tayo, Arpan Acharya, James J. Cai, Siddappa N. Byrareddy, Thangavel Samikkannu   +7 more
wiley   +1 more source

Successful lamivudine therapy for chronic hepatitis B in the family [PDF]

Vojnosanitetski Pregled, 2006
Background. Hepatitis B virus infection is a global public health problem since it is a leading cause of liver cirrhosis and hepatocellular carcinoma. An optimal treatment is needed to reduce mortality.
Nožić Darko
doaj   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B

, 2004
Adefovir dipivoxil possesses potent in vitro and in vivo antiviral activity in wild-type hepatitis B. This study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compared with ongoing lamivudine therapy in ...
Peters, Marion G, Ebrahimi, R, Martin, Paul, Trepo, C, Buggisch, P, Gray Df, D f, GS-00-461 Study Grp, Kleber, K, Hann Hw, H w, Heathcote, E Jenny, Rubin, R, Bourliere, M, Kowdley, K, Sullivan, M, Xiong, S, Brosgart, Carol L   +15 more
core   +1 more source

Green HPLC quantification method of lamivudine, zidovudine and nevirapine with identification of related substances in tablets

Green Chemistry Letters and Reviews, 2022
A green HPLC method for lamivudine (3TC), zidovudine (AZT) and nevirapine (NVP) determination in fixed-dose combination tablets was developed using ethanol as both one of the mobile phases and the solvent for sample preparation. This method was validated
Ludivine Vieira-Sellaï, Mercedes Quintana, Ousmane Diop, Olivier Mercier, Sebastien Tarrit, Nawal Raimi, Alassan Ba, Benoit Maunit, Marie-Josephe Galmier   +8 more
doaj   +1 more source

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule, Maryam Habib, Rija Khalid, Jessie Tu, Deborah Yoong, Jaris Swidrovich, Wale Ajiboye, Patrick O'Byrne, Ameeta E. Singh, Jean‐Guy Baril, Tatiana Sotindjo, Mark W. Hull, Darrell H. S. Tan   +12 more
wiley   +1 more source

A Novel Method for Large-Scale Synthesis of Lamivudine through Cocrystal Formation of Racemic Lamivudine with (S)-(−)-1,1′-Bi(2-naphthol) [(S)-(BINOL)]

, 2016
A large-scale synthesis of (−)-[2R,5S]-4-amino-1- [2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidin-2-one (lamivudine) through resolution of racemic lamivudine by cocrystal formation with (S)- BINOL has been demonstrated.
Bhairab Nath Roy (2374660), Umesh P. Aher (2374654), Girij Pal Singh (2374666), Dhananjai Srivastava (2374663), Harishchandra S. Jadhav (2374651), Manmeet B. Saini (2374657)   +5 more
core   +2 more sources